The Microbiome Effect: Link Found Between Immunotherapy Success and Gut Flora

摘要

Pharmaceutical companies have turned their gaze to the microbiome in hopes of understanding the discrepancy between treatment effectiveness, specifically in highly promising cancer immunotherapies. Recent data has shed light on the link between the human microbiome and the effectiveness of immunotherapeutics. Although the microbiome's role in modulating these therapies is still somewhat opaque, now would be an opportune time for pharmaceutical firms to consider strategic partnerships with companies that specialize in human microbiome research to make their immunotherapeutic stand out in a crowd that is already big and growing. Some estimates have cancer immunotherapeutic sales reaching USD $50b by the middle of next decade - up from $6b in 2016.